NA Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 CELL SOURCE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET APPLICATION COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 52
5 NORTH AMERICA MEDICAL CARTS MARKET: REGULATIONS 54
5.1 REGULATION IN U.S. 54
5.2 REGULATION IN CANADA 55
5.3 REGULATION IN EUROPE 55
5.4 REGULATION IN INDIA 55
5.5 REGUALTION IN JAPAN 56

6 MARKET OVERVIEW 58
6.1 DRIVERS 60
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS 60
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS 60
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES 61
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY 63
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT 64
6.2 RESTRAINT 65
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS 65
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 65
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS 66
6.3 OPPORTUNITIES 66
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS 66
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE 67
6.3.3 SURGE IN HEALTHCARE EXPENDITURE 67
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 68
6.4 CHALLENGES 69
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE 69
6.4.2 LACK OF SKILLED PROFESSIONALS 69
6.4.3 STRINGENT REGULATORY FRAMEWORK 69
7 IMPACT OF COVID-19 ON THE NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 71
7.1 IMPACT ON PRICE 71
7.2 IMPACT ON DEMAND 71
7.3 IMPACT ON SUPPLY CHAIN 72
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 72
7.5 CONCLUSION 73
8 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE 74
8.1 OVERVIEW 75
8.2 SKIN CELLS 77
8.2.1 FIBROBLAST 78
8.2.2 KERATINOCYTES 78
8.2.3 ADIPOSE DERIVED STEM CELLS 79
8.2.4 HEPATOCYTES 79
8.2.5 MELANOCYTES 79
8.2.6 NEURAL STEM CELLS 79
8.2.7 OTHERS 79
8.3 BLOOD CELLS 79
8.3.1 PERIPHERAL BLOOD 80
8.3.2 CORD BLOOD ENDOTHELIAL CELLS 80
8.3.3 CORD BLOOD STEM CELLS 80
8.3.4 OTHERS 80
9 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE 81
9.1 OVERVIEW 82
9.2 HUMAN IPSCS 85
9.3 MOUSE IPSCS 85
10 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT 87
10.1 OVERVIEW 88
10.2 CONSUMABLES & KITS 91
10.2.1 REPROGRAMMING KITS 92
10.2.2 MEDIA 92
10.2.3 TRANSFECTION KITS 92
10.2.4 CELL IDENTIFICATION KITS 92
10.2.5 ACCESSORIES 92
10.2.6 OTHERS 92
10.3 SERVICES 92
10.4 INSTRUMENTS 93
10.4.1 IMAGING SYSTEMS 94
10.4.2 ELECTROPORATION DEVICE 94
10.4.3 INCUBATORS 94
10.4.4 OTHERS 94
11 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION 95
11.1 OVERVIEW 96
11.2 DRUG DISCOVERY AND DEVELOPMENT 99
11.3 ACADEMIC RESEARCH 99
11.4 DISEASE MODELLING 100
11.5 CELLULAR THERAPY 101
11.6 REGENERATIVE MEDICINE 101
11.7 TOXICOLOGY SCREENING 102
11.8 STEM CELL BANKING 103
11.9 3D BIOPRINTING 103
11.10 OTHERS 104
12 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER 105
12.1 OVERVIEW 106
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 109
12.3 RESEARCH LABORATORIES 109
12.4 DIAGNOSTIC LABORATORIES 110
12.5 OTHERS 111
13 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL 112
13.1 OVERVIEW 113
13.2 DIRECT TENDER 115
13.3 RETAIL SALES 116
14 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION 117
14.1 NORTH AMERICA 118
14.1.1 U.S. 125
14.1.2 CANADA 128
14.1.3 MEXICO 131
15 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE 134
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 134
16 SWOT ANALYSIS 135
17 COMPANY PROFILE 136
17.1 FUJIFILM CORPORATION 136
17.1.1 COMPANY SNAPSHOT 136
17.1.2 REVENUE ANALYSIS 136
17.1.3 COMPANY SHARE ANALYSIS 137
17.1.4 PRODUCT PORTFOLIO 137
17.1.5 RECENT DEVELOPMENT 138
17.1.5.1 ACQUISITION 138

17.2 THERMO FISHER SCIENTIFIC INC. 139
17.2.1 COMPANY SNAPSHOT 139
17.2.2 REVENUE ANALYSIS 139
17.2.3 COMPANY SHARE ANALYSIS 140
17.2.4 PRODUCT PORTFOLIO 140
17.2.5 RECENT DEVELOPMENTS 143
17.2.5.1 EVENT 143
17.2.5.2 ACQUISITION 144
17.3 LONZA. 145
17.3.1 COMPANY SNAPSHOT 145
17.3.2 REVENUE ANALYSIS 145
17.3.3 COMPANY SHARE ANALYSIS 146
17.3.4 PRODUCT PORTFOLIO 146
17.3.5 RECENT DEVELOPMENTS 147
17.3.5.1 EXPANSION 147
17.4 MERCK KGAA 148
17.4.1 COMPANY SNAPSHOT 148
17.4.2 REVENUE ANALYSIS 148
17.4.3 COMPANY SHARE ANALYSIS 149
17.4.4 PRODUCT PORTFOLIO 149
17.4.5 RECENT DEVELOPMENT 152
17.4.5.1 AGREEMENT 152
17.5 EVOTEC SE. 153
17.5.1 COMPANY SNAPSHOT 153
17.5.2 REVENUE ANALYSIS 153
17.5.3 COMPANY SHARE ANALYSIS 154
17.5.4 PRODUCT PORTFOLIO 154
17.5.5 RECENT DEVELOPMENTS 154
17.5.5.1 AGREEMENT 154
17.5.5.2 COLLABORATION 155
17.6 APPLIED STEMCELL. 156
17.6.1 COMPANY SNAPSHOT 156
17.6.2 PRODUCT PORTFOLIO 156
17.6.3 RECENT DEVELOPMENTS 162
17.6.3.1 PRODUCT LAUNCH 162
17.7 AXOL BIOSCIENCE LTD. 163
17.7.1 COMPANY SNAPSHOT 163
17.7.2 PRODUCT PORTFOLIO 163
17.7.3 RECENT DEVELOPMENTS 166
17.7.3.1 MERGER 166
17.7.3.2 PRODUCT LAUNCH 167
17.8 CELL APPLICATIONS, INC. 168
17.8.1 COMPANY SNAPSHOT 168
17.8.2 PRODUCT PORTFOLIO 168
17.8.3 RECENT DEVELOPMENT 169
17.8.3.1 PARTNERSHIP 169
17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 170
17.9.1 COMPANY SNAPSHOT 170
17.9.2 REVENUE ANALYSIS 170
17.9.3 PRODUCT PORTFOLIO 171
17.9.4 RECENT DEVELOPMENT 171
17.9.4.1 ACQUISITION 171
17.10 CITIUS PHARMACEUTICALS, INC. 172
17.10.1 COMPANY SNAPSHOT 172
17.10.2 PRODUCT PORTFOLIO 172
17.10.3 RECENT DEVELOPMENT 172
17.10.3.1 AGREEMENT 172
17.11 CORNING INCORPORATED 173
17.11.1 COMPANY SNAPSHOT 173
17.11.2 REVENUE ANALYSIS 173
17.11.3 PRODUCT PORTFOLIO 174
17.11.4 RECENT DEVELOPMENT 174
17.11.4.1 AGREEMENT 174
17.12 FATE THERAPEUTICS 175
17.12.1 COMPANY SNAPSHOT 175
17.12.2 PRODUCT PORTFOLIO 175
17.12.3 RECENT DEVELOPMENT 175
17.12.3.1 CLINICAL TRIAL 175
17.13 GENECOPOEIA, INC. 176
17.13.1 COMPANY SNAPSHOT 176
17.13.2 PRODUCT PORTFOLIO 176
17.13.3 RECENT DEVELOPMENT 176
17.14 HOPSTEM BIOTECHNOLOGY LLC. 177
17.14.1 COMPANY SNAPSHOT 177
17.14.2 PRODUCT PORTFOLIO 177
17.14.3 RECENT DEVELOPMENT 177
17.14.3.1 PARTNERSHIP 177

17.15 HORIZON DISCOVERY LTD. 178
17.15.1 COMPANY SNAPSHOT 178
17.15.2 PRODUCT PORTFOLIO 178
17.15.3 RECENT DEVELOPMENT 178
17.16 LUMACYTE 179
17.16.1 COMPANY SNAPSHOT 179
17.16.2 PRODUCT PORTFOLIO 179
17.16.3 RECENT DEVELOPMENT 180
17.16.3.1 COLLABORATION 180
17.17 R & D SYSTEMS, INC. 181
17.17.1 COMPANY SNAPSHOT 181
17.17.2 REVENUE ANALYSIS 181
17.17.3 PRODUCT PORTFOLIO 182
17.17.4 RECENT DEVELOPMENT 183
17.18 REPROCELL INC. 184
17.18.1 COMPANY SNAPSHOT 184
17.18.2 PRODUCT PORTFOLIO 184
17.18.3 RECENT DEVELOPMENTS 185
17.18.3.1 COLLABORATION 185
17.18.3.2 FACILITY EXPANSION 186
17.18.3.3 SERVICE LAUNCH 186
17.19 TAKARA BIO INC. 187
17.19.1 COMPANY SNAPSHOT 187
17.19.2 REVENUE ANALYSIS 187
17.19.3 PRODUCT PORTFOLIO 188
17.19.4 RECENT DEVELOPMENTS 188
17.19.4.1 NEW FACILITY LAUNCH 188
17.20 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY) 189
17.20.1 COMPANY SNAPSHOT 189
17.20.2 REVENUE ANALYSIS 189
17.20.3 PRODUCT PORTFOLIO 190
17.20.4 RECENT DEVELOPMENT 190
17.20.4.1 ACQUISITION 190
18 QUESTIONNAIRE 191
19 RELATED REPORTS 195